Lipid Droplet-Accumulating Microglia as a Therapeutic Node in Neurodegenerative Disease
ACS Chemical Neuroscience · 17.06.2026 · 17 (12) · 2302-2318
DOI: 10.1021/acschemneuro.6c00284 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 02.06.2026. Verfasst von Siqi Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: Microglia, Neurodegenerative Diseases, Lipid Droplets. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Jiangsu Provincial Department of Education, Nanjing University of Chinese Medicine, Six Talent Peaks Project in Jiangsu Province.
Abstract (Originalsprache)
Neurodegenerative disorders increasingly reflect failures of cellular state control rather than the linear accumulation of a single toxic lesion. Microglia become trapped in maladaptive states in which inflammatory activation is decoupled from effective cargo processing. Lipid droplet-accumulating microglia (LDAM) represent a recurrent convergence state across aging and neurodegeneration, characterized by persistent neutral lipid sequestration, reduced phagocytosis-to-degradation capacity, oxidative amplification, and chronic but functionally inefficient inflammation. LDAM emerges when lipid substrate influx exceeds the capacity of cholesterol efflux, lysosomal lipophagy, and mitochondrial β-oxidation, converting lipid droplets from transient buffers into stable metabolic anchors. This entrenchment is reinforced by mitochondrial exhaustion, vacuolar H+-ATPase-linked lysosomal deacidification, and inflammasome/interferon locking, often further amplified by cGAS-STING signaling. Together, these constraints converge on a state of metabolic-epigenetic locking that sustains permissive chromatin landscapes at pro-inflammatory loci. On this basis, state-resetting strategies are considered that rebalance lipid flux, restore organelle clearance capacity, and transiently restrain inflammatory amplification, while spatial multiomics and fluid biomarkers are discussed as candidate tools for stage- and niche-resolved stratification of combination interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
ORCID-Profile: Qichun Zhang
Förderung
- Jiangsu Provincial Department of Education
- Nanjing University of Chinese Medicine
- Six Talent Peaks Project in Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Guo, S., Zhang, Q., Guo, R., Fu, L., Zhu, H., & Zhang, Q. (2026). Lipid Droplet-Accumulating Microglia as a Therapeutic Node in Neurodegenerative Disease. ACS Chemical Neuroscience, 17(12), 2302-2318. https://doi.org/10.1021/acschemneuro.6c00284
Vancouver
Guo S, Zhang Q, Guo R, Fu L, Zhu H, Zhang Q. Lipid Droplet-Accumulating Microglia as a Therapeutic Node in Neurodegenerative Disease. ACS Chemical Neuroscience. 2026;17(12):2302-2318. doi:10.1021/acschemneuro.6c00284
BibTeX
@article{Guo2026,
author = {Guo, Siqi and Zhang, Qingyu and Guo, Rui and Fu, Liyuan and Zhu, Huaxu and Zhang, Qichun},
title = {Lipid Droplet-Accumulating Microglia as a Therapeutic Node in Neurodegenerative Disease},
journal = {ACS Chemical Neuroscience},
year = {2026},
volume = {17},
number = {12},
pages = {2302--2318},
doi = {10.1021/acschemneuro.6c00284}
}
EUVIMED